therivabio.com (TOVX) - Company Cash Volume

Theriva Biologics, Inc. (TOVX) is expanding the deployment of VCN-01 oncolytic drugs to combat tumors by developing methods to unmask cancer cells for the immune system. Production relies on the audit of precision cultivation systems within cleanrooms. This cash availability chart confirms these data, where the 0.01 metric determines the status of the company's liquidity parameter and financial margin of safety.
Analytical breakdowns for Theriva Biologics, Inc.

This indicator tracks the total balance of liquid assets, allowing for an assessment of the capital burn rate and the issuer's financial autonomy. By analyzing the volume of physical cash, an investor determines the company's ability to fund operating expenses without resorting to external borrowing. For Theriva Biologics, Inc. (TOVX), these resources are critical when implementing automated laboratories to scale immunotherapy. Robotization reduces personnel costs, optimizing liquidity expenditure. A stable cash reserve confirms the viability of the business model.